Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer

Cancer Letters

Volumn 330, Issue 1, 2013, Pages 74-83

  Zhao, Ying Zheng ^a   Dai, Dan Dan ^a   Lu, Cui Tao ^a   Chen, Li Juan ^a   Lin, Min ^a   Shen, Xiao Tong ^a   Li, Xiao Kun ^a   Zhang, Ming ^a   Jiang, Xi ^a   Jin, Rong Rong ^a   Li, Xing ^a   Lv, Hai Feng ^a   Cai, Lu ^b   Huang, Pin Tong ^c,d  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Department of Ultrasound ^*  (China)

Author keywords

Cancer targeted therapy; Epirubicin; Multidrug resistance; Propylene glycol liposomes

Indexed keywords

EPIRUBICIN; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS MEMBRANE; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; PROPYLENE GLYCOL; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84872873907     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.031     Document Type: Article

References (31)

1. Li X., Li P., Zhang Y., Zhou Y., Chen X., Huang Y., Liu Y. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res. 2010, 27(8):1498-1511.
2. Stein W.D., Bates S.E., Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr. Drug Targets 2004, 5(4):333-346.
3. Wang Y., Yu L., Han L., Sha X., Fang X. Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm. 2007, 337(1-2):63-73.
4. Lukianova-Hleb Ekaterina Y., Belyanin Andrey, Kashinath Shruti, Wu Xiangwei, Lapotko Dmitri O. Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells. Biomaterials 2012, 33(6):1821-1826.
5. Z. Hodurova, L. Ferreira, F. Sánchez-Juanes, A. Dominguez, Y. Gbelska, Cytosolic proteome of Kluyveromyces lactis affected by the multidrug resistance regulating transcription factor KlPdr1p, J. Proteom., 2012 July 12 (Epub ahead of print).
6. X. Zhang, S. Guo, R. Fan, M. Yu, F. Li, C. Zhu, Y. Gan, Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells, Biomaterials, 2012 July 12 (Epub ahead of print).
7. G. Caceres, R.W. Robey, L. Sokol, K.L. McGraw, J. Clark, N.J. Lawrence, S.M. Sebti, M. Wiese, List AF. HG-829 is a potent non-competitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1, Cancer Res., 2012 July 3 (Epub ahead of print).
8. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., Charlton P. In vitro and in vivo reversal of P-Glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 61(2):749-758.
9. Chen L.M., Liang Y.J., Zhang X., Su X.D., Dai C.L., Wang F.P., Yan Y.Y., Tao L.Y., Fu L.W. Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res. 2009, 29(11):4597-4604.
10. Zhang L., Lu C.T., Li W.F., Cheng J.G., Tian X.Q., Zhao Y.Z., Li X., Lv H.F., Li X.K. Physical characterization and cellular uptake of propylene glycol liposomes in vitro. Drug Dev. Ind. Pharm. 2012, 38(3):365-371.
11. Y.Z. Zhao, D.D. Dai, C.T. Lu, H.F. Lv, Y. Zhang, X. Li, W.F. Li, Y. Wu, L. Jiang, X.K. Li, P.T. Huang, L.J. Chen, M. Lin, Using acoustic cavitation to enhance chemotherapy of DOX liposomes: experiment in vitro and in vivo. Drug Dev. Ind. Pharm., 2011 December 21 (Epub ahead of print).
12. L. Sande, M. Sanchez, J. Montes, A.J. Wolf, M.A. Morgan, A. Omri, G.Y. Liu, Liposomal encapsulation of vancomycin improves killing of methicillin-resistant staphylococcus aureus in a murine infection model, J. Antimicrob. Chemother., 2012 June 2 (Epub ahead of print).
13. S.K. Bobbala, P.R. Veerareddy, Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery, J. Liposome Res., 2012 July 4 (Epub ahead of print).
14. Martins S., Sarmento B., Ferreira D.C., Souto E.B. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. .J Nanomedicine 2007, 2(4):595-607.
15. Smola M., Vandamme T., Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine 2008, 3(1):1-19.
16. Goyal P., Goyal K., Vijaya Kumar S.G., Singh A., Katare O.P., Mishra D.N. Liposomal drug delivery systems-clinical applications. Acta Pharm. 2005, 55(1):1-25.
17. Konduri K.S., Nandedkar S., Rickaby D.A., Düzgünes N., Gangadharam P.R. The use of sterically stabilized liposomes to treat asthma. Methods Enzymol. 2005, 391:413-427.
18. Fenske D.B., Cullis P.R. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 2005, 391:7-40.
19. Ichihara H., Zako K., Komizu Y., Goto K., Ueoka R. Therapeutic effects of hybrid liposomes composed of phosphatidylcholine and docosahexaenoic acid on the hepatic metastasis of colon carcinoma along with apoptosis in vivo. Biol. Pharm. Bull. 2011, 34(6):901-905.
20. Sha X., Guo J., Chen Y., Fang X. Effect of phospholipid composition on pharmacokinetics and biodistribution of epirubicin liposomes. J. Liposome Res. 2012, 22(1):80-88.
21. M. Sterba, O. Popelova, A. Vavrova, E. Jirkovsky, P. Kovarikova, V. Gersl, T. Simunek, Oxidative stress, redox signaling and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection, Antioxid. Redox. Signal, 2012 July 15 (Epub ahead of print).
22. Pohlen U., Buhr H.J., Berger G. Improvement of biodistribution with PEGylated liposomes containing docetaxel with degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases: a study in CC-531 liver tumor-bearing WAG RIJ rats. Anticancer Res. 2011, 31(1):153-159.
23. Hsu W.H., Lee B.H., Pan T.M. Effects of red mold dioscorea on oral carcinogenesis in DMBA-induced hamster animal model. Food Chem. Toxicol. 2011, 49(6):1292-1297.
24. Shi H.Y., Zhang W., Liang R., Abraham S., Kittrell F.S., Medina D., Zhang M. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res. 2001, 61(18):6945-6951.
25. Kim H., Park H., Lee J., Kim T.H., Lee E.S., Oh K.T., Lee K.C., Youn Y.S. Highly porous largepoly (lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 2011, 32:1685-1693.
26. Kim H., Lee J., Kim T.H., Lee E.S., Oh K.T., Lee D.H., Park E.S., Bae Y.H., Lee K.C., Youn Y.S. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityla-cylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm. Res. 2011, 28:2008-2019.
27. Wang H.G., Zhai G.X., Lü Q.Z., Ling P.X. Preparation and characterization of chitosan coatedpuerarinliposome. Zhong Yao Cai 2007, 30(1):89-92.
28. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hyper-sensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996, 56:3626-3629.
29. Arsenaut A.L., Ling V., Kartner N. Altered plasma membrane ultrastructure in multidrug resistant cells. Biochim. Biophys. Acta 1988, 938:315-321.
30. Batrakova E.V., Miller D.W., Li S., Alakhov V.Y., Kabanov A.V., Elmquist W.F. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 2001, 296(2):551-557.
31. Evers R., Kool M., Smith A.J., Deemter L.V., Haas M.D., Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer 2000, 83:366-374.